Abstract
The growth fractions of 160 mammary carcinomas and 30 benign mammary lesions were determined in situ by immunostaining with the monoclonal antibody Ki-67. Benign lesions had a mean value of 3% Ki-67 positive cells, whereas the mean value of mammary carcinomas was 16.6%. A comparison of the mean values of Ki-67 positive cells with the histological grade of the tumours showed a correlation between these two variables--that is, histological grade 1 showed 9%, grade 2 16%, and grade 3 26% proliferating cells. Considering the individual Ki-67 values in the different histological grades, it was evident that there was considerable scatter in the number of proliferating cells, so that the proliferation rates of grades 1, 2, and 3 overlapped each other. This indicates a dissociation between histological grade of malignancy and size of the growth fraction in most breast cancers. Follow up studies are needed to establish which of the two variables--that is, morphological degree of malignancy, or the proportion of Ki-67 positive cells--correlates better with response to treatment and survival in individual cases.
MeSH Terms
Antibodies, Monoclonal
Breast Diseases/pathology
Breast Neoplasms/pathology
Carcinoma, Intraductal, Noninfiltrating/pathology
Female
Humans
Mitosis
Prognosis
Chemicals
Antibodies, Monoclonal
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gerdes J
Lelle R J
Pickartz H
Heidenreich W
Schwarting R
Kurtsiefer L
Stauch G
Stein H
References (15)
15 references, click to expand
-
Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.
Hematol Oncol. 1984 Oct-Dec;2(4):365-71
PMID: 6396192
-
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J Immunol. 1984 Oct;133(4):1710-5
PMID: 6206131
-
Prognostic factors in cancer of the female breast. II. Reproducibility of histopathologic classification.
Cancer. 1966 Jan;19(1):75-82
PMID: 5901409
-
Proliferation-dependent cytotoxicity of anticancer agents: a review.
Cancer Res. 1975 Oct;35(10):2619-30
PMID: 1098765
-
Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices.
Cancer Res. 1979 Oct;39(10):4042-7
PMID: 476641
-
Analysis of reproducibility of subjective grading systems for breast carcinoma.
J Clin Pathol. 1979 Oct;32(10):979-85
PMID: 521499
-
Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival.
Cancer Res. 1980 Jun;40(6):1890-6
PMID: 7371021
-
Kinetic parameters and the course of the disease in breast cancer.
Cancer. 1981 Mar 1;47(5):937-43
PMID: 7226045
-
Rapid growth rate in breast cancer: a confounding variable in adjuvant-chemotherapy trials.
Lancet. 1982 Jun 12;1(8285):1343-5
PMID: 6123647
-
Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.
Int J Cancer. 1982 Oct 15;30(4):445-59
PMID: 6754630
-
Prediction of early course of breast carcinoma by thymidine labeling.
Cancer. 1983 May 15;51(10):1879-86
PMID: 6831353
-
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.
Int J Cancer. 1983 Jan 15;31(1):13-20
PMID: 6339421
-
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
J Histochem Cytochem. 1984 Feb;32(2):219-29
PMID: 6198355
-
The proliferative index (PI) of human breast cancer as obtained by flow cytometry.
Pathol Res Pract. 1984 Mar;178(4):315-22
PMID: 6728713
-
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.
Br J Cancer. 1957 Sep;11(3):359-77
PMID: 13499785